![pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons](../news/img/healthcare/pills_rapid_release_pills_By_Katy_Warner_from_Orlando_FL_USA_[CC-BY-SA-3.0_(http_creativecommons.org_licenses_by-sa_3.0)]_via_Wikimedia_Commons.jpg)
The shareholders have not assumed some changes at the revenue all over the July to September 30 2022 reporting cycle at the company. However, they observe IMUXs' operating loss which was at $-20.116 millions, during the matching time.
The smartest policy to interpret the third quarter of 2022 earnings season outcome, at the prevailing stage of the organization. It isan easy to measure the operating loss of the third quarter of 2021, which was $-18.387 millions.
Seeking to prompt the successful revenue sources, businesses frequently experience distinctively choppy period. May be one of this, is the fiscal third quarter of 2022, where the deficit has widen to $-21.224 millions.
Immunic Inc is expected to report next financial recent numbers on February 23, 2023.